Morgan Stanley has maintained its overweight rating on Divi’s Laboratories and set a target price of Rs 7,185, suggesting an upside of nearly 15% from the current market price of Rs 6,268.00.
The brokerage noted that Divi’s Q4FY25 revenue came in at Rs 25.8 billion, up 12% year-on-year and in line with estimates. For the full year, revenue growth stood at 19% YoY.
EBITDA rose 21% YoY to Rs 8.8 billion, coming in 7% above Morgan Stanley’s estimates. The EBITDA margin expanded by 253 basis points year-on-year to 34.3%, while gross margin improved by 122 basis points to 62.1% during the quarter.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to consult certified financial professionals before making any investment decisions.
